Compare Johnson & Johnson (JNJ) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kymera Therapeutics Inc. Common Stock — how do they compare? Johnson & Johnson trades at $257.82 (market cap $599.12B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Johnson & Johnson is far larger — about 67.5× Kymera Therapeutics Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| JNJ | KYMR | |
|---|---|---|
Market Cap | $599.12B | $8.87B |
Volume | 16,640,951 | 779,107 |
Sector | Health | Health |
52-Week High | $278.43 | $127.31 |
52-Week Low | $186.00 | $55.80 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $627.40B | $8.26B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
